SIGA TECHNOLOGIES INCSIGAEarnings & Financial Report
SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
SIGA Q4 FY2025 Key Financial Metrics
Revenue
$3.8M
Gross Profit
$804.5K
Operating Profit
N/A
Net Profit
N/A
Gross Margin
21.2%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-95.3%
SIGA TECHNOLOGIES INC Q4 FY2025 Financial Summary
SIGA TECHNOLOGIES INC reported revenue of $3.8M (down 95.3% YoY) for Q4 FY2025, with a net profit of N/A (down 111.9% YoY) (N/A margin). Cost of goods sold was $3.0M.
Key Financial Metrics
| Total Revenue | $3.8M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 21.2% |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
SIGA TECHNOLOGIES INC Annual Revenue by Year
SIGA TECHNOLOGIES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $94.6M).
SIGA TECHNOLOGIES INC Quarterly Revenue & Net Profit History
SIGA TECHNOLOGIES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.8M | -95.3% | N/A | N/A |
| Q3 FY2025 | $2.6M | -73.8% | $-6.4M | -243.0% |
| Q2 FY2025 | $81.1M | +271.9% | $35.5M | 43.7% |
| Q1 FY2025 | $7.0M | -72.3% | $-408.2K | -5.8% |
| Q4 FY2024 | $81.5M | -30.1% | $45.8M | 56.2% |
| Q3 FY2024 | $10.0M | +8.4% | $1.3M | 13.4% |
| Q2 FY2024 | $21.8M | +271.0% | $1.8M | 8.4% |
| Q1 FY2024 | $25.4M | +205.5% | $10.3M | 40.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.4M | $21.8M | $10.0M | $81.5M | $7.0M | $81.1M | $2.6M | $3.8M |
| YoY Growth | 205.5% | 271.0% | 8.4% | -30.1% | -72.3% | 271.9% | -73.8% | -95.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $243.1M | $192.7M | $195.4M | $244.3M | $247.1M | $235.3M | $231.6M | $219.5M |
| Liabilities | $78.2M | $25.1M | $25.9M | $28.5M | $30.9M | $26.0M | $28.1M | $20.6M |
| Equity | $165.0M | $167.6M | $169.4M | $215.8M | $216.1M | $209.3M | $203.5M | $198.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.1M | $6.0M | $-7.4M | $56.3M | $7.1M | $63.1M | $-9.8M | $43.5M |